Evidence map›Paper›PMID 33543465›Full record

ArticleAdvances in experimental medicine and biology2021

Nanotechnology for the Development of Nanovaccines in Cancer Immunotherapy.

Maria Aurora Grimaudo

Abstract read
PubMed Publisher
In one paragraph

Article in Advances in experimental medicine and biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Applications of Nanobiotechnology in Medicine.Life (Basel, Switzerland) · 2026
    Review
  2. Potentiating Cancer Immune TherapyFrontiers in cell and developmental biology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Maria Aurora GrimaudoNano-Oncology Unit, Translational Medical Oncology Group, Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain. Maria.Aurora.Grimaudo@sergas.es.
Instituto de Investigación Sanitaria de Santiago · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Up until now, surgery, radiation, and chemotherapy remain the conventional methods used in cancer treatment. However, these treatments are widely associated with severe side effects due to toxicity on normal cells. Consequently, there is an urgent need for novel therapeutic approaches that are able to effectively and selectively target tumor cells without any adverse effects on normal cells. Among the new approaches, cancer immunotherapy seems promising in the fight against tumors thanks to its prolonged efficacy and lower toxicity compared to the traditional treatments.Research studies suggested that both adjuvants and antigens are essential to induce optimal anti-tumor immunity. Among the different delivery strategies, nanotechnology offers several advantages for the design of cancer vaccines. Indeed, nanocarriers can protect the encapsulated antigens and/or adjuvant from enzymatic degradation, sustain and control the release for the entrapped cargo, and enhance the immune responses.Several studies reported that different physical characteristics of nanoparticles affect their uptake in cells and the potential to induce cellular responses. Among them, particle size and surface chemistry resulted the most influent.Clinical trials and recent research papers on the use of nanotechnology in cancer immunotherapy support the idea that this strategy could be successful as weapon against cancer in the near future.

Indexed as

Cancer VaccinesNanoparticlesNeoplasmsHumansImmunotherapyNanotechnologyCancer VaccinesCancer immunotherapyCell membrane coated nanoparticlesGold nanoparticlesHydrogel nanoparticlesImmune checkpoint inhibitorsInorganic nanoparticlesLiposomesMicellesNanotechnologyNanovaccinesPolymeric nanoparticles

Identifiers

PMID33543465
OpenAlexW3127080404

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.